US 12,134,599 B2
Solid forms
He Hongyan, Shanghai (CN); Jiang Siyi, Shanghai (CN); Urs Schwitter, Little Falls, NJ (US); Pascal Jean Claude Dott, Littlefalls, NJ (US); Ralph Diodone, Little Falls, NJ (US); Nicole Wyttenbach, Little Falls, NJ (US); and Olaf Grassmann, Little Falls, NJ (US)
Assigned to River 3 Renal Corp., New York, NY (US); and Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed by River 3 Renal Corp., New York, NY (US); and Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed on Oct. 11, 2023, as Appl. No. 18/484,722.
Application 18/484,722 is a continuation of application No. 17/939,203, filed on Sep. 7, 2022, granted, now 11,814,354.
Claims priority of provisional application 63/243,813, filed on Sep. 14, 2021.
Claims priority of application No. 202111049581.4 (CN), filed on Sep. 8, 2021.
Prior Publication US 2024/0300895 A1, Sep. 12, 2024
Int. Cl. C07D 213/64 (2006.01)
CPC C07D 213/64 (2013.01) [C07B 2200/13 (2013.01)] 20 Claims
 
1. A crystalline form of 5-(3,4-dichlorophenyl)-N-((1R,2R)-2-hydroxycyclohexyl)-6-(2,2,2-trifluoroethoxy)nicotinamide, monohydrate (Form B), characterized by a powder X-ray diffraction pattern having a characteristic peak in degrees 2θ at about 6.5, 11.2, 13.0, 17.2, 19.4, 22.5, 23.4, 26.0, 28.2, 29.8, 32.7, and 34.0, wherein the powder X-ray diffraction pattern was obtained using Cu Kα radiation.